Market niche Target interventional cardiology centers treating bifurcation lesions with Tryton's Side Branch Stent system as a dedicated bifurcation device, highlighting FDA approval and proprietary Tri-zone technology to differentiate from conventional DES strategies.

Clinical leadership Leverage the track record of Tryton's leadership and partnerships, including past CEO transitions and collaborations with major distributors like Cardinal Health, to engage hospital procurement and highlight stability in strategic initiatives.

Regulatory edge Emphasize regulatory approval status and ongoing post-approval study momentum to reassure hospitals about adoption risk, while positioning for expanding use in UAE/MEA or other regions through distributor networks.

Channel expansion Capitalize on historical distribution partnerships and funding activity to open conversations with large distributors and health systems about broader adoption, training, and bundled solutions for bifurcation interventions.

Financial traction Present opportunities tied to unit economics of a niche bifurcation device in a <$1M revenue company, stressing potential for high-value cases, contract manufacturing, and co-marketing with strategic partners to scale visibility.